Amanta Healthcare has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI). The issue size will be up to 1,25,00,000 equity shares with face value of Rs 10 each.
The company propose to utilize Rs 7,000 lakh of its net proceeds for funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat and Rs 3,000 lakh for funding capital expenditure requirements towards purchase of equipment, plant and machinery for setting up new line for SVP at Hariyala, Kheda, Gujarat.
Amanta Healthcare, located in Ahmedabad (Gujarat) has emerged as India’s most versatile manufacturer and marketer of sterile dosages in Aseptic Blow -- Fill -- Seal (BFS) and Injection Stretch Blow Moulding (ISBM) space with well integrated operations -- F & D to full scale manufacturing & capability to develop customized solutions (containers, closures & drug delivery).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: